Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives

Current Pharmaceutical Design

Volumn 19, Issue 21, 2013, Pages 3827-3840

  Moutzouri, Elisavet ^a   Tsimihodimos, Vasilis ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Biomarkers; Cardiovascular disease; HsCRP; Inflammation; Lp PLA2; PAF acetylhydrolase; SPLA2

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DARAPLADIB; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SECRETORY PHOSPHOLIPASE A2; VARESPLADIB METHYL; VERY LOW DENSITY LIPOPROTEIN;

ABNORMAL FECES; ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL STUDY; FECES MALODOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MORBIDITY; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOCIOECONOMICS; URINE MALODOR; URINE ODOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; PHOSPHOLIPASES A2, SECRETORY; RISK ASSESSMENT; RISK FACTORS;

EID: 84878641966     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990307     Document Type: Review

References (171)

1. Futterman LG and Lemberg L. Fifty percent of patients with coronary artery disease do not have any of the conventional risk factors. Am J Crit Care 1998; 7: 240-4.
2. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
3. Ford ES, Giles WH, and Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43: 1791-6.
4. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990; 265: 9682-7.
5. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68.
6. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261: 511-4.
7. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19: 2909-17.
8. Tellis CC and Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009; 1791: 327-38.
9. Rallidis LS, Tellis CC, Lekakis J, et al. Lipoprotein-associated phospholipase a(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol 2012; 60: 2053-60.
10. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51: 2264-73.
11. Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD. Distribution of PAF-acetylhydrolase activity in human plasma lowdensity lipoprotein subfractions. Biochim Biophys Acta 1994; 1213: 34-8.
12. Karabina SA, Elisaf MC, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis AD. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro. Atherosclerosis 1996; 125: 121-34.
13. Samanta U, Bahnson BJ. Crystal structure of human plasma platelet-activating factor acetylhydrolase: structural implication to lipoprotein binding and catalysis. J Biol Chem 2008; 283: 31617-24.
14. Tjoelker LW, Eberhardt C, Unger J, et al. Plasma plateletactivating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad. J Biol Chem 1995; 270: 25481-7.
15. Tjoelker LW, Wilder C, Eberhardt C, et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 1995; 374: 549-53.
16. Quarck R, De Geest B, Stengel D, et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 2001; 103: 2495-500.
17. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res 1989; 30: 305-15.
18. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 1991; 266: 11095-103.
19. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest 1997; 27: 595-602.
20. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of lowdensity lipoprotein: use of a novel inhibitor. Biochem J 1999; 338 (Pt 2): 479-87.
21. Kita T, Kume N, Ochi H, et al. Induction of endothelial plateletderived growth factor-B-chain and intercellular adhesion molecule-1 by lysophosphatidylcholine. Ann N Y Acad Sci 1997; 811: 70-5.
22. Kume N, Cybulsky MI, Gimbrone MA, Jr. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138-44.
23. Ozaki H, Ishii K, Arai H, Kume N, and Kita T. Lysophosphatidylcholine activates mitogen-activated protein kinases by a tyrosine kinase-dependent pathway in bovine aortic endothelial cells. Atherosclerosis 1999; 143: 261-6.
24. Nilsson J, Dahlgren B, Ares M, et al. Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor. Arterioscler Thromb Vasc Biol 1998; 18: 13-9.
25. Goncalves I, Edsfeldt A, Ko NY, et al. Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 2012; 32: 1505-12.
26. Stafforini DM, Sheller JR, Blackwell TS, et al. Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem 2006; 281: 4616-23.
27. Kim JY, Hyun YJ, Jang Y, et al. Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. Am J Clin Nutr 2008; 88: 630-7.
28. Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2523-9.
29. Herrmann J, Mannheim D, Wohlert C, et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J 2009; 30: 2930-8.
30. Wang WY, Zhang J, Wu WY, et al. Inhibition of lipoproteinassociated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. PLoS One 2011; 6: e23425.
31. Hu MM, Zhang J, Wang WY, et al. The inhibition of lipoproteinassociated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin 2011; 32: 1253-8.
32. Suchindran S, Rivedal D, Guyton JR, et al. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet 2010; 6: e1000928.
33. Stafforini DM, Satoh K, Atkinson DL, et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996; 97: 2784-91.
34. Ishihara M, Iwasaki T, Nagano M, et al. Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients. J Hum Genet 2004; 49: 302-7.
35. Jang Y, Waterworth D, Lee JE, et al. Carriage of the V279F null allele within the gene encoding Lp-PLA is protective from coronary artery disease in South Korean males. PLoS One 2011; 6: e18208.
36. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-44.
37. Suzuki T, Solomon C, Jenny NS, et al. Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail 2009; 2: 429-36.
38. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000; 343: 1148-55.
39. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 2005; 165: 2479-84.
40. Koenig W, Meisinger C, Baumert J, Khuseyinova N, Lowel H. Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies. Gesundheitswesen 2005; 67 Suppl 1: S62-7.
41. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001; 38: 1302-6.
42. Hatoum IJ, Cook NR, Nelson JJ, Rexrode KM, Rimm EB. Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. Am Heart J 2011; 161: 516-22.
43. Rana JS, Arsenault BJ, Despres JP, et al. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J 2011; 32: 336-44.
44. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005; 26: 137-44.
45. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-8.
46. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000; 150: 413-9.
47. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 2007; 27: 2463-9.
48. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol 2006; 26: 2517-22.
49. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoproteinassociated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26: 1586-93.
50. May HT, Horne BD, Anderson JL, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 2006; 152: 997-1003.
51. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoproteinassociated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113: 1745-52.
52. Ryu SK, Mallat Z, Benessiano J, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation 2012; 125: 757-66.
53. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111: 570-5.
54. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2006; 26: 631-6.
55. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC. Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 2007; 191: 377-83.
56. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007; 190: 388-96.
57. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110: 1903-8.
58. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 2008; 51: 913-9.
59. Deedwania PC, Maki KC, Dicklin MR, Stone NJ, Ballantyne CM, Davidson MH. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). J Cardiometab Syndr 2006; 1: 295-300.
60. Persson M, Hedblad B, Nelson JJ, and Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1411-6.
61. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn 2007; 7: 511-7.
62. Balafa OC, Karabina SA, Pappas CA, Elisaf M, Tselepis AD, Siamopoulos KC. Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins. Nephron Physiol 2004; 97: p45-52.
63. Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC. Plasma and Lp(a)-associated PAFacetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int 1999; 56: 2276-85.
64. McConnell JP and Jaffe AS. Variability of lipoprotein-associated phospholipase A2 measurements. Clin Chem 2008; 54: 932-3.
65. Eisaf M Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003; 66: 2069-73.
66. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 2236-43.
67. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002; 22: 306-11.
68. Katsiki N, Mikhailidis DP, Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011; 29: 2493-4; author reply 2494.
69. Ridker PM, Macfadyen JG, Wolfert RL, Koenig W. Relationship of Lipoprotein-Associated Phospholipase A2 Mass and Activity with Incident Vascular Events among Primary Prevention Patients Allocated to Placebo or to Statin Therapy:An Analysis from the JUPITER Trial. Clin Chem 2012; 58: 877-86.
70. White HD, Simes J, Barnes E, et al. Changes in Lp-PLA2 Activity in Secondary Prevention Predict Coronary Events and Treatment Effect by Pravastatin in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Trial. Circulation 2011; 124: A14857.
71. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101: 51F-57F.
72. Jellinger PS, Smith DA, Mehta AE, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocrine Practice 2012; 18 Suppl 1: 1-78.
73. Tselepis AF, Rizzo M, Goudevenos IA. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). Curr Pharm Des 2011; 17: 3656-61.
74. Wilensky RL, Shi Y, Mohler ER, 3rd, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.
75. Mohler ER, 3rd, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebocontrolled study. J Am Coll Cardiol 2008; 51: 1632-41.
76. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008; 118: 1172-82.
77. White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010; 160: 655-61.
78. O'Donoghue ML, Braunwald E, White HD, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J 2011; 162: 613-619 e1.
79. Stafforini DM, McIntyre TM, Zimmerman GA, and Prescott SM. Platelet-activating factor acetylhydrolases. J Biol Chem 1997; 272: 17895-8.
80. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001; 89: 298-304.
81. Webb NR, Bostrom MA, Szilvassy SJ, van der Westhuyzen DR, Daugherty A, de Beer FC. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23: 263-8.
82. Ivandic B, Castellani LW, Wang XP, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler Thromb Vasc Biol 1999; 19: 1284-90.
83. Rosengren B, Peilot H, Umaerus M, et al. Secretory phospholipase A2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol 2006; 26: 1579-85.
84. Hanasaki K, Yamada K, Yamamoto S, et al. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 2002; 277: 29116-24.
85. Karabina SA, Brocheriou I, Le Naour G, et al. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J 2006; 20: 2547-9.
86. Bostrom MA, Boyanovsky BB, Jordan CT, et al. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice. Arterioscler Thromb Vasc Biol 2007; 27: 600-6.
87. Ghesquiere SA, Gijbels MJ, Anthonsen M, et al. Macrophagespecific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition. J Lipid Res 2005; 46: 201-10.
88. Boyanovsky B, Zack M, Forrest K, and Webb NR. The capacity of group V sPLA2 to increase atherogenicity of ApoE-/-and LDLR-/-mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler Thromb Vasc Biol 2009; 29: 532-8.
89. Menschikowski M, Kasper M, Lattke P, et al. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995; 118: 173-81.
90. Hurt-Camejo E, Andersen S, Standal R, et al. Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on lowdensity lipoproteins. Arterioscler Thromb Vasc Biol 1997; 17: 300-9.
91. Elinder LS, Dumitrescu A, Larsson P, Hedin U, Frostegard J, Claesson HE. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol 1997; 17: 2257-63.
92. Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, Webb NR. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol 2004; 24: 762-7.
93. Sato H, Kato R, Isogai Y, et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008; 283: 33483-97.
94. Nakano T, Ohara O, Teraoka H, and Arita H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett 1990; 261: 171-4.
95. Kuwata H, Nakatani Y, Murakami M, Kudo I. Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts. J Biol Chem 1998; 273: 1733-40.
96. Hamaguchi K, Kuwata H, Yoshihara K, et al. Induction of distinct sets of secretory phospholipase A(2) in rodents during inflammation. Biochim Biophys Acta 2003; 1635: 37-47.
97. Hartford M, Wiklund O, Mattsson Hulten L, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006; 108: 55-62.
98. Boyanovsky BB, van der Westhuyzen DR, Webb NR. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A-and CD36-independent process that involves cellular proteoglycans. J Biol Chem 2005; 280: 32746-52.
99. Pruzanski W, Lambeau L, Lazdunsky M, Cho W, Kopilov J, Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta 2005; 1736: 38-50.
100. Hurt-Camejo E, Camejo G, and Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000; 11: 465-71.
101. Kleinman Y, Krul ES, Burnes M, Aronson W, Pfleger B, and Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 1988; 29: 729-43.
102. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenaseinduced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. Biochemistry 1998; 37: 9203-10.
103. Leitinger N, Watson AD, Hama SY, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999; 19: 1291-8.
104. Rouault M, Le Calvez C, Boilard E, et al. Recombinant production and properties of binding of the full set of mouse secreted phospholipases A2 to the mouse M-type receptor. Biochemistry 2007; 46: 1647-62.
105. Oestvang J, Anthonsen MW, Johansen B. Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholinestimulated monocyte arachidonic acid release. FEBS Lett 2003; 555: 257-62.
106. Ishimoto Y, Yamada K, Yamamoto S, Ono T, Notoya M, Hanasaki K. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta 2003; 1642: 129-38.
107. Boekholdt SM, Keller TT, Wareham NJ, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005; 25: 839-46.
108. Mallat Z, Benessiano J, Simon T, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 2007; 27: 1177-83.
109. Mallat Z, Steg PG, Benessiano J, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1249-57.
110. Kugiyama K, Ota Y, Takazoe K, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999; 100: 1280-4.
111. Kugiyama K, Ota Y, Sugiyama S, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000; 86: 718-22.
112. O'Donoghue ML, Mallat Z, Morrow DA, et al. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. Clin Chem 2011; 57: 1311-7.
113. Liu PY, Li YH, Tsai WC, et al. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003; 24: 1824-32.
114. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 2009; 30: 2742-8.
115. Smart BP, Oslund RC, Walsh LA, Gelb MH. The first potent inhibitor of mammalian group X secreted phospholipase A2: elucidation of sites for enhanced binding. J Med Chem 2006; 49: 2858-60.
116. Oslund RC, Cermak N, and Gelb MH. Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2. J Med Chem 2008; 51: 4708-14.
117. Fraser H, Hislop C, Christie RM, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/-mice. J Cardiovasc Pharmacol 2009; 53: 60-5.
118. Shaposhnik Z, Wang X, Trias J, Fraser H, and Lusis AJ. The synergistic inhibition of atherogenesis in apoE-/-mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 2009; 50: 623-9.
119. Rosenson RS, Hislop C, McConnell D, et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial. Lancet 2009; 373: 649-58.
120. Rosenson RS, Elliott M, Stasiv Y, and Hislop C. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. Eur Heart J 2011; 32: 999-1005.
121. Nicholls SJ, Cavender MA, Kastelein JJ, et al. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovasc Pharmacother 2012; 26: 71-5.
122. Ridker PM and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004; 109: 1955-9.
123. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of Creactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.
124. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
125. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
126. Danesh J, Muir J, Wong YK, Ward M, Gallimore JR, Pepys MB. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 1999; 20: 954-9.
127. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92: 17K-22K.
128. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
129. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
130. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139-47.
131. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
132. Ridker PM, Rifai N, Rose L, Buring JE, and Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
133. Cushman M, Arnold AM, Psaty BM, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112: 25-31.
134. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
135. Ray KK, Cannon CP, Cairns R, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-24.
136. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 2000; 321: 199-204.
137. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-38.
138. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012; 308: 788-95.
139. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med 2008; 359: 2195-207.
140. Shishehbor MH and Hazen SL. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleve Clin J Med 2009; 76: 37-44.
141. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004; 109: 1349-53.
142. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009; 38: 217-31.
143. Hamer M, Chida Y, and Stamatakis E. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases. Am J Cardiol 2009; 104: 538-42.
144. Mieczkowska J, Mosiewicz J, Barud W, and Kwasniewski W. Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome. Arch Med Sci 2011; 7: 634-41.
145. Hak AE, Stehouwer CD, Bots ML, et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-91.
146. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005; 165: 221-6.
147. Khor LL, Muhlestein JB, Carlquist JF, et al. Sex-and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med 2004; 117: 657-64.
148. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945-51.
149. Gupta J, Mitra N, Kanetsky PA, et al. Association between Albuminuria, Kidney Function, and Inflammatory Biomarker Profile. Clin J Am Soc Nephrol 2012.
150. Tzoulaki I, Siontis KC, Ioannidis JP. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ 2011; 343: d6829.
151. Zwaka TP, Hombach V, and Torzewski J. C-reactive proteinmediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-7.
152. Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96: 714-6.
153. Wadham C, Albanese N, Roberts J, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 2004; 109: 2116-22.
154. Bhakdi S, Torzewski M, Klouche M, and Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-54.
155. Zhang YX, Cliff WJ, Schoefl GI, and Higgins G. Coronary Creactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis 1999; 145: 375-9.
156. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 1386-92.
157. Devaraj S, Yun JM, Adamson G, Galvez J, Jialal I. C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res 2009; 84: 479-84.
158. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009; 206: 61-8.
159. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008; 49: 1015-23.
160. Valleggi S, Devaraj S, Dasu MR, Jialal I. C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase. Clin Chem 2010; 56: 1345-8.
161. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-20.
162. Pepys MB, CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005; 25: 1091-4.
163. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, and Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359: 1897-908.
164. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009; 302: 37-48.
165. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 496-507.
166. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 483-95.
167. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis 2012; 223: 1-68.
168. Barylski M, Malyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney-what was new in 2011? Arch Med Sci 2011; 7: 1055-66.
169. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358: 2107-16.
170. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
171. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109: 837-42.